The FDA has approved Novavax’s COVID-19 vaccine, Nuvavoxid, for use in adults 65 and older and in individuals ages 12-64 who have at least one underlying health condition. The approval is based on ...

Novavax (NASDAQ:NVAX) on Wednesday announced late-stage trial data to indicate that its COVID-19-Influenza Combination (CIC) vaccine candidate and its stand-alone influenza vaccine candidate generated ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

(CNN) — After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up ...

Vaccine maker Novavax says its shot is highly effective against COVID-19 and also protects against variants. The Maryland-based company on Monday announced results from a large, late-stage study in ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. File Photo by Jim Lo Scalzo/EPA-EFE May 18 (UPI) --The U.S. Food and Drug ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide ...

The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck told ...

HOUSTON, Texas (KTRK) -- Pfizer and Moderna doses are making their way to cities across the country, but it's simply not enough to meet the need. "Right now, there's a huge demand for a limited supply ...

May 18 (UPI) --The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay. The agency approved the vaccine only for people 65 and older and ...